The top varieties in the field of potential immunosuppressants sell for 30 billion yuan!
With the coming Oil & Gas Asia Exhibition in Pakistan, ECHEMI rolls out a new bulk purchasing activity for its new and old customers. This activity will be valid before March 16 when the exhibition come to the end. The more you buy, the more money you will save.
How to join this bulk purchasing?
You can enjoy the most favorable prices via three steps:
First, you should come to the home page of ECHEMI, then you can see the the following page:
Second, input your demand and submit the inquiry.
Third, ECHEMI will give you a reply within 1 working day after receiving your inquiry.
Opportunity knocks but once! Come on, seize this opportunity right now!
Looking for chemical products? Let suppliers reach out to you!
You May Interested In
β-Nicotinamide Adenine Dinucleotide High Quality NAD+ CAS 53-84-9 Exclusive Production Factory CAS NO.53-84-9
$75/UNIT FOB
Best Service Pharmaceutical Producer CAS 2381089-83-2 Retatrutide 5mg Weight Loss Peptide
$70/MT FOB
2026-07-05
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Pfizer Warns Germany: Drug Pricing Could Put Investment at Risk
-
J&J VAT Dispute Threatens Free Medicine Access in Britain
-
Alchem Fined $576,000 for Role in EU Pharmaceutical Cartel
-
Pharma Companies to See 11 Percent Growth in Sales and EBITDA in Q1FY26
-
Moderna to Cut 10 Percent of Staff as COVID Vaccine Sales Plunge Stock Drops 4 Percent
-
Sipcam Nichino Brasil Unveils Soleado Fungicide at Hortitec 2025
-
Sun Pharma Halts US Expansion Amid 25 Percent Tariff Threat Net Profit Drops 20 Percent
-
Bayer Sets Aside $1.37 Billion for Roundup Lawsuits Raises 2025 Sales Forecast to €48 Billion
-
Trump Pressures 17 Pharma CEOs to Match US Drug Prices with Global Lows September 29 Deadline Set
-
JB Pharma Q1 Net Profit Surges 14 Percent to ₹202 Crore Revenue Hits ₹1094 Crore with 30 Percent EBITDA Margin
Recommend Reading
-
Mounjaro Reduces Heart Events by 8 Percent More Than Trulicity in 13,000-Patient Diabetes Trial
-
Lilly Eyes Fast-Track Approval for Oral Weight-Loss Drug in U.S.
-
U.S. Health Chief Says No Evidence Linking Tylenol to Autism
-
Merck and Eisai Halt Late-Stage Trial for Liver Cancer Therapy
-
India Strengthens Drug Approval Oversight with Expanded CDSCO Powers
-
HAMR Plans $520 Million Methanol SAF Facility 125 Million Liters Output to Cut Airline Emissions
-
FDA Dye Tracker Raises Reformulation Pressure Across Food Brands
-
Weak Decline in TDI Market in September
-
Premium Global Chemical Sourcing Requests (8-12 Nov 2025)
-
Snack Tests Put Red 40, Titanium Dioxide and BHT Back Under Pressure